Department of Epidemiology and Public Health, National University of Singapore, Singapore.
Int J Cancer. 2012 May 1;130(9):2103-10. doi: 10.1002/ijc.26206. Epub 2011 Nov 17.
Population-based studies have shown a concordance of breast cancer survival among first-degree relatives (FDRs), suggesting a heritable component. Reasons for such heritability remain to be elucidated. We aimed to determine whether association of breast cancer survival among FDRs is linked to shared patient and tumor characteristics or type of treatment. At the population-based Geneva Breast Cancer Registry, we identified 162 FDR pairs diagnosed with breast cancer. We categorized FDRs into poor, medium and good familial survival risk groups according to breast cancer-specific survival of their proband (mother or sister). We compared patient, tumor and treatment characteristics between categories and calculated standardized mortality ratios (SMRs) and adjusted disease-specific mortality for each group. Breast cancer patients in the poor familial survival risk group were more likely to be diagnosed at later stages than those in the good familial survival risk group. Similarly, they had higher SMRs than those in the medium and good survival risk groups (18.7, 95% confidence interval [CI]: 9.4-33.5 vs. 16.5, 95% CI: 7.5-31.3 and 9.4, 95% CI: 3.4-20.4, respectively). After adjustment for patient and tumor characteristics and type of treatment, women in the poor familial survival risk group were almost five times more likely to die of breast cancer than those in the good familial survival risk group (adjusted hazard ratio 4.8, 95% CI: 1.4-16.4). Our study shows that breast cancer prognosis clusters within families and suggests that the hereditary component is independent of patient and tumor characteristics and type of treatment.
基于人群的研究表明,一级亲属(FDR)的乳腺癌生存情况具有一致性,提示存在遗传因素。但遗传因素的具体原因仍有待阐明。我们旨在确定 FDR 之间的乳腺癌生存关联是否与患者和肿瘤特征或治疗类型有关。在基于人群的日内瓦乳腺癌登记处,我们确定了 162 对 FDR 患有乳腺癌。我们根据其先证者(母亲或姐妹)的乳腺癌特异性生存情况,将 FDR 分为不良、中等和良好家族生存风险组。我们比较了不同组之间的患者、肿瘤和治疗特征,并计算了每个组的标准化死亡率比(SMR)和调整后的疾病特异性死亡率。不良家族生存风险组的乳腺癌患者比良好家族生存风险组更有可能被诊断为晚期。同样,他们的 SMR 也高于中等和良好生存风险组(18.7,95%置信区间[CI]:9.4-33.5 比 16.5,95% CI:7.5-31.3 和 9.4,95% CI:3.4-20.4)。在调整了患者和肿瘤特征以及治疗类型后,不良家族生存风险组的女性死于乳腺癌的风险几乎是良好家族生存风险组的五倍(调整后的危险比 4.8,95% CI:1.4-16.4)。我们的研究表明,乳腺癌的预后在家族中聚集,并提示遗传因素独立于患者和肿瘤特征以及治疗类型。